
TY  - JOUR
TI  - Abstracts
JO  - Wound Repair and Regeneration
JA  - Wound Repair Regen
VL  - 20
IS  - 5
SN  - 1067-1927
UR  - https://doi.org/10.1111/j.1524-475X.2012.00834.x
DO  - doi:10.1111/j.1524-475X.2012.00834.x
SP  - A83
EP  - A121
PY  - 2012
ER  - 

AU  - Wu, Jau-Ching
AU  - Mummaneni, Praveen V.
C7  - pp. 170-192
TI  - Neurosurgical Use of Bone Allografts and Dural Substitutes
SN  - 9781405198257
UR  - https://doi.org/10.1002/9781118498453.ch8
DO  - doi:10.1002/9781118498453.ch8
SP  - 170-192
KW  - anterior cervical discectomy and fusion
KW  - Wolff's law
KW  - autograft
KW  - allograft
KW  - demineralized bone matrix
KW  - bone morphogenic protein
KW  - cage
KW  - ceramics
KW  - Creutzfeldt–Jakob disease
KW  - xenogenic graft
PY  - 2012
AB  - Summary The use of autografts, allografts, and synthetic materials in neurosurgery continues to increase. Bone grafts are frequently used for spinal fusion and dural grafts are often utilized in cranial tumor cases. Autografts have previously been the gold standard for such cases since they have excellent graft incorporation without the risk of rejection or disease transmission, however, their drawback is limited supply and potential donor site morbidity. Allografts are an acceptable alternative due to their relative abundance, availability of various sizes and shapes, handling characteristics, and elimination of procurement-related complications for the patient. Strict guidelines for allograft donor screening and advances in processing techniques have reduced the risk of disease transmission but some processing treatments can compromise graft mechanical strength. Nonetheless, allografts may still rarely elicit an inflammatory response, be rejected, or transmit disease. New synthetic materials are another option but they may not incorporate into host tissues as well as autografts or allografts. Neurosurgeons face the perpetual challenge of utilizing the appropriate graft to meet the specific needs of each patient
ER  - 

TY  - JOUR
TI  - Short Papers
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 105
IS  - S5
SN  - 9781405198257
UR  - https://doi.org/10.1002/bjs.10970
DO  - doi:10.1002/bjs.10970
SP  - 12
EP  - 66
PY  - 2018
ER  - 

TY  - JOUR
AU  - American Society for Parenteral and Enteral Nutrition
TI  - Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients
JO  - Journal of Parenteral and Enteral Nutrition
JA  - Journal of Parenteral and Enteral Nutrition
VL  - 26
IS  - 1S
SN  - 9781405198257
UR  - https://doi.org/10.1177/0148607102026001011
DO  - doi:10.1177/0148607102026001011
SP  - 1SA
EP  - 138SA
PY  - 2002
ER  - 

TY  - JOUR
AU  - Cash, Jenna L
AU  - Bena, Stefania
AU  - Headland, Sarah E
AU  - McArthur, Simon
AU  - Brancaleone, Vincenzo
AU  - Perretti, Mauro
TI  - Chemerin15 inhibits neutrophil-mediated vascular inflammation and myocardial ischemia-reperfusion injury through ChemR23
JO  - EMBO reports
VL  - 14
IS  - 11
SN  - 9781405198257
UR  - https://doi.org/10.1038/embor.2013.138
DO  - doi:10.1038/embor.2013.138
SP  - 999
EP  - 1007
KW  - chemerin peptide
KW  - inflammation
KW  - intravital microscopy
KW  - neutrophil
KW  - resolution
PY  - 2013
AB  - Neutrophil activation and adhesion must be tightly controlled to prevent complications associated with excessive inflammatory responses. The role of the anti-inflammatory peptide chemerin15 (C15) and the receptor ChemR23 in neutrophil physiology is unknown. Here, we report that ChemR23 is expressed in neutrophil granules and rapidly upregulated upon neutrophil activation. C15 inhibits integrin activation and clustering, reducing neutrophil adhesion and chemotaxis in vitro. In the inflamed microvasculature, C15 rapidly modulates neutrophil physiology inducing adherent cell detachment from the inflamed endothelium, while reducing neutrophil recruitment and heart damage in a murine myocardial infarction model. These effects are mediated through ChemR23. We identify the C15/ChemR23 pathway as a new regulator and thus therapeutic target in neutrophil-driven pathologies.
ER  - 

TY  - JOUR
TI  - Free Papers
JO  - Clinical & Experimental Ophthalmology
VL  - 36
IS  - s1
SN  - 9781405198257
UR  - https://doi.org/10.1111/j.1442-9071.2008.01745.x
DO  - doi:10.1111/j.1442-9071.2008.01745.x
SP  - A1
EP  - A61
PY  - 2008
ER  - 

TY  - JOUR
TI  - Ards
JO  - Acta Anaesthesiologica Scandinavica
VL  - 40
IS  - s109
SN  - 9781405198257
UR  - https://doi.org/10.1111/j.1399-6576.1996.tb04577.x
DO  - doi:10.1111/j.1399-6576.1996.tb04577.x
SP  - 61
EP  - 74
PY  - 1996
ER  - 

TY  - JOUR
TI  - Short papers
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 102
IS  - s1
SN  - 9781405198257
UR  - https://doi.org/10.1002/bjs.9729
DO  - doi:10.1002/bjs.9729
SP  - 9
EP  - 118
PY  - 2015
ER  - 

TY  - JOUR
TI  - Abstracts from the 41st Neural Interfaces Conference June 23–25, 2014 Dallas, Texas, USA
JO  - Neuromodulation: Technology at the Neural Interface
JA  - Neuromodulation: Technology at the Neural Interface
VL  - 17
IS  - 5
SN  - 9781405198257
UR  - https://doi.org/10.1111/ner.12232
DO  - doi:10.1111/ner.12232
SP  - e40
EP  - e127
PY  - 2014
ER  - 

TY  - JOUR
TI  - Abstracts for The Royal Australian and New Zealand College of Psychiatrists
JO  - Australian and New Zealand Journal of Psychiatry
VL  - 35
IS  - 4
SN  - 9781405198257
UR  - https://doi.org/10.1046/j.1440-1614.2001.0350040A1.x
DO  - doi:10.1046/j.1440-1614.2001.0350040A1.x
SP  - A1
EP  - A30
PY  - 2001
ER  - 

TY  - JOUR
TI  - Oral presentations
JO  - International Journal of Paediatric Dentistry
VL  - 15
IS  - s2
SN  - 9781405198257
UR  - https://doi.org/10.1111/j.1365-263X.2005.00709.x
DO  - doi:10.1111/j.1365-263X.2005.00709.x
SP  - 1
EP  - 31
PY  - 2005
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Vox Sanguinis
JA  - Vox Sang
VL  - 112
IS  - S1
SN  - 9781405198257
UR  - https://doi.org/10.1111/vox.12530
DO  - doi:10.1111/vox.12530
SP  - 5
EP  - 295
PY  - 2017
ER  - 

TY  - JOUR
AU  - Zandvoort, A.
AU  - Lodewijk, M.E.
AU  - De Boer, N.K.
AU  - Dammers, P.M.
AU  - Kroese, F.G.M.
AU  - Timens, W.
TI  - CD27 expression in the human splenic marginal zone: the infant marginal zone is populated by naive B cells
JO  - Tissue Antigens
VL  - 58
IS  - 4
SN  - 9781405198257
UR  - https://doi.org/10.1034/j.1399-0039.2001.580403.x
DO  - doi:10.1034/j.1399-0039.2001.580403.x
SP  - 234
EP  - 242
KW  - B cells
KW  - CD27
KW  - human
KW  - infant
KW  - marginal zone
KW  - spleen
PY  - 2001
AB  - Abstract: The splenic marginal zone of adult humans contains B cells, of which most express CD27, an antigen only recently identified as a marker for somatically mutated memory B cells. We investigated whether and to which extent the developing marginal zone in infants and children is populated by either memory (CD27+) or naive (CD27?) B cells. Frozen sections of 32 spleens of infants and children ranging in age from 6 days to 15 years and 6 adult spleens were investigated. The expression of CD27 in combination with monoclonal antibodies against CD3, CD21, IgM, IgD and ASM-1 was analyzed by immunohistochemistry. The marginal zone was already present at 4 months after birth but CD21 expression was observed first after 2 years. CD27-positive marginal zone B cells were observed firstly 2 years after birth and increased in number to adult levels at the age of 5 years. We demonstrated that the MZ of infants and young children is populated by naive B cells, which are replaced by memory B cells in a time frame of 2 to 5 years. Before the age of 2 years, although present, memory B cells appear to be unable to colonize the marginal zone. Because of the absence of memory B cells in the marginal zone, the immune system of a child is not capable to initiate a rapid secondary humoral immune response comparable to the adult immune response.
ER  - 

C7  - pp. 487-971
TI  - Spanish to English
SN  - 9781118237977
UR  - https://doi.org/10.1002/9781118797907.ch2
DO  - doi:10.1002/9781118797907.ch2
SP  - 487-971
KW  - A effect
KW  - A-fetoprotein
KW  - A particle
KW  - A position
KW  - A radiator
KW  - Ability
KW  - Abiogenesis
KW  - Ablandador
KW  - Abono
KW  - Abrazadera
KW  - Bacilo
KW  - Bacarina
KW  - Bacitracina
KW  - Bacteria
KW  - Baja temperatura
KW  - Cabrerita
KW  - Cacao
KW  - Cacodilato
KW  - Cacotelina
KW  - Cadaleno
KW  - Dacita
KW  - Dactilina
KW  - Dactinomicina
KW  - Dafnetina
KW  - Dafnita
KW  - Easina
KW  - Ebonita
KW  - Ebriedad
KW  - Ebullidor
KW  - Eccema
KW  - Fabianol
KW  - Fabricar
KW  - Fagocitosis
KW  - Fagocito
KW  - Fagarina
KW  - Gabapentina
KW  - Gadinina
KW  - Gadolinio
KW  - Gadolinita
KW  - Galvanismo
KW  - Habitat
KW  - Hachis
KW  - Hafnio
KW  - Halocarburo
KW  - Halocromismo
KW  - Latroqenesls
KW  - Ibuprofeno
KW  - Icosano
KW  - Icosanol
KW  - Icosilo
KW  - Jaborina
KW  - Jacinto
KW  - Jade
KW  - Jadeita
KW  - Jaspe
KW  - Kappa
KW  - Kanamicina
KW  - Kawa kawa
KW  - Kernita
KW  - Ketamina
KW  - Laberinto
KW  - Labilidad
KW  - Labradorita
KW  - Lactama
KW  - Lactamida
KW  - Macroelectrodo
KW  - Macrociclo
KW  - Maclado
KW  - Macrociclo
KW  - Macroquimica
KW  - Nabam
KW  - Nabilone
KW  - Nacrita
KW  - Nadolol
KW  - Nadorita
KW  - Objetivo
KW  - Oblea
KW  - Oblicuidad
KW  - Obligaci6n
KW  - Obtener
KW  - Pagodita
KW  - Paladar
KW  - Paladato
KW  - Palamina
KW  - Paleocerebelo
KW  - Quelato
KW  - Quemador
KW  - Quemadura
KW  - Queratina
KW  - Queratinasa
KW  - Racemasa
KW  - Racemato
KW  - Racemizar
KW  - Racimo
KW  - Raciocinio
KW  - Sabineno
KW  - Sabinol
KW  - Sabor
KW  - Saborear
KW  - Saborizante
KW  - Tableta
KW  - Taconita
KW  - Tacrina
KW  - Tanasa
KW  - Tanato
KW  - Ulexina
KW  - Ulmina
KW  - Ultiva
KW  - Ultracentrifuga
KW  - Ultrafiltrado
KW  - Vacante
KW  - Vacio
KW  - Vacuna
KW  - Valeriana
KW  - Valerilo
KW  - Wagnerita
KW  - Warfarina
KW  - Wavellita
KW  - Weber
KW  - Wellbutrin
KW  - Xanax
KW  - Xantano
KW  - Xantato
KW  - Xantenilo
KW  - Xanteno
KW  - Yeso
KW  - Yodato
KW  - Yodilo
KW  - Yodita
KW  - Yodeosina
KW  - Zaleplon
KW  - Zaratita
KW  - Zarontin
KW  - Zeaxantina
KW  - Zeina
PY  - 2001
AB  - Summary This chapter contains sections titled: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ER  - 

TY  - JOUR
TI  - British Society for Matrix Biology Spring 2019 Meeting: “Stroma, Niche, Repair”
JO  - International Journal of Experimental Pathology
JA  - Int. J. Exp. Path.
VL  - 100
IS  - 4
SN  - 9781118237977
UR  - https://doi.org/10.1111/iep.12332
DO  - doi:10.1111/iep.12332
SP  - A1
EP  - A45
PY  - 2019
ER  - 

C7  - pp. 417-576
TI  - Glossary and Index
SN  - 9781119975892
UR  - https://doi.org/10.1002/9781119977452.index
DO  - doi:10.1002/9781119977452.index
SP  - 417-576
PY  - 2019
ER  - 

TY  - JOUR
TI  - Irish Society of Urology Book of Abstracts
JO  - BJU International
JA  - BJU Int
VL  - 114
IS  - S2
SN  - 9781119975892
UR  - https://doi.org/10.1111/bju.12873
DO  - doi:10.1111/bju.12873
SP  - 17
EP  - 41
PY  - 2014
ER  - 

TY  - JOUR
AU  - LOCKE, JUSTIN T
TI  - Climate change-induced migration in the Pacific Region: sudden crisis and long-term developments1
JO  - The Geographical Journal
VL  - 175
IS  - 3
SN  - 9781119975892
UR  - https://doi.org/10.1111/j.1475-4959.2008.00317.x
DO  - doi:10.1111/j.1475-4959.2008.00317.x
SP  - 171
EP  - 180
KW  - Kiribati
KW  - Tuvalu
KW  - climate change
KW  - migration
KW  - analysis
KW  - migrants
PY  - 2009
AB  - With so many other social, economic and environmental factors at work establishing linear, causative relationships between anthropogenic climate change and population dynamics it has been difficult to pinpoint the specific human consequences of climate change on respective populations. Qualitative information was examined based on interviewees? testimonies and personal experience, as well as a descriptive analysis of population records, climate-change related impacts, and consequences of uneven development in the Republic of Kiribati and Tuvalu, two low-lying atoll nations in the Pacific region taken as examples to illustrate the issues involved. Strong evidence was found that recent influxes in population movements to urban central islands from rural outer islands experienced in these countries can be attributed to a combination of the adverse impacts of climate change and socioeconomic factors inherit in small island developing states. Moreover, internal migrants cannot be accommodated in their states of origin, putting pressure on local infrastructure and services. This, combined with a recent population boom, has led to a decline in human development indicators and a general livelihood decline.
ER  - 

TY  - JOUR
AU  - Fernandes, Célio Jr. da Costa
AU  - Veiga, Mariana R.
AU  - Peracoli, Maria Terezinha Serrão
AU  - Zambuzzi, Willian F.
TI  - Modulatory effects of silibinin in cell behavior during osteogenic phenotype
JO  - Journal of Cellular Biochemistry
JA  - J Cell Biochem
VL  - 120
IS  - 8
SN  - 9781119975892
UR  - https://doi.org/10.1002/jcb.28616
DO  - doi:10.1002/jcb.28616
SP  - 13413
EP  - 13425
KW  - bone
KW  - flavonoid
KW  - inflammation
KW  - osteoblast
KW  - remodeling
KW  - silibinin
PY  - 2019
AB  - Abstract Natural molecules, such as flavonoid, are very welcome strategies to modulate bone turnover. This prompted us to comprehend better the effect of silibinin on osteoblast metabolism, mainly considering intracellular pathways able to drive cell adhesion to differentiation. By exploring in vitro approaches, our data show a modulatory effect of the silibinin (200??g/mL) on the osteoblast intracellular signaling, contributing with decisive pathways governing cell adhesion, differentiation, and further mineralization, recapitulating important stages of osteogenesis. Within the first 24?hours of adhesion (acute stage), osteoblasts respond to silibinin by rearranging their cytoskeleton and start mechanisms responsible to extracellular matrix (ECM) remodeling, which reach intense profile at 28 days of treatment (chronic stage) by favoring matrix metalloproteinases (MMPs-2, and -9) activities, concomitant to mineralizing phenotype. Importantly, silibinin seems to reprogram genes related to inflammatory landscape and significantly upmodulating osteoprotegerin (>25 fold-changes), signaling molecule involved with osteoclastogenesis. Altogether, our results show for the first time that silibinin drives in vitro osteoblast differentiation by requiring specific intracellular signaling. In conjunction, this molecular landscape contributes to understand the effect of silibinin on osteoblasts performance and open novel therapeutic possibilities to silibinin in bone disorders, such as osteoporosis.
ER  - 

TY  - JOUR
TI  - ASBMR 29th Annual Meeting
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 22
IS  - S1
SN  - 9781119975892
UR  - https://doi.org/10.1002/jbmr.5650221411
DO  - doi:10.1002/jbmr.5650221411
SP  - s452
EP  - s500
PY  - 2007
ER  - 
